Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

We're sorry, but this trial is no longer enrolling volunteers.

NC-HEM-14-6: Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)


The purpose of this study is to assess the safety and tolerability of BMS-986004 when administered in subjects with ITP.


Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.

Inclusion and Exclusion Criteria

  • ≥18 years old, diagnosed with persistent or chronic ITP

  • Secondary immune thrombocytopenia
  • Drug induced thrombocytopenia


Please contact Gangothri Namasivayam to learn more about where you can participate in this trial. Please use the contact form on the right side.

Powered by SC CTSI